Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esketamine - Altamira Therapeutics

Next Previous
Drug Profile

Esketamine - Altamira Therapeutics

Alternative Names: (s)-ketamine; AM-101; Esketamine otic gel; Keyzilen

Latest Information Update: 06 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Auris Medical; INSERM; University of Montpellier I
  • Developer Altamira Therapeutics
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Tinnitus

Highest Development Phases

  • Suspended Tinnitus

Most Recent Events

  • 16 May 2023 Esketamine is available for licensing as of 16 May 2023. https://altamiratherapeutics.com/rna-programs
  • 16 May 2023 Suspended - Phase-II for Tinnitus in Netherlands (Intratympanic) prior to May 2023
  • 16 May 2023 Suspended - Phase-III for Tinnitus in Austria, Hungary, Czech Republic, United Kingdom, South Korea, Spain, Poland, Canada, USA, Germany, Belgium (Intratympanic) prior to May 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top